Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Skin metastases not suitable for or patient refusing definitive surgical resection and radiation. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Skin metastases not suitable for or patient refusing definitive surgical resection and radiation. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Skin metastases not suitable for or patient refusing definitive surgical resection and radiation. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: (Cohort 2) Any concurrent systemic therapy is allowed secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Age at least 18 years. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients must have adequate organ and bone marrow function as defined below: secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |